Related Experiment Video
Updated: May 13, 2025

Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways
Ellis G Jaffray1, Michael H Tatham1, Barbara Mojsa1
1Division of Molecular, Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dundee, UK.
Abstract:
Arsenic effectively treats acute promyelocytic leukemia by inducing SUMO and ubiquitin-dependent degradation of the promyelocytic leukemia (PML)-retinoic acid receptor alpha oncogenic fusion protein. However, some patients relapse with arsenic-resistant disease because of missense mutations in PML. To determine the mechanistic basis for arsenic resistance, PML-/- cells were reconstituted with YFP fusions of wild-type PML-V and two common patient mutants: A216T and L217F. Both mutants were resistant to degradation by arsenic but for different biochemical reasons. Arsenic did not trigger SUMOylation of A216T PML, which failed to recruit the SUMO-targeting ubiquitin ligases RNF4 and TOPORS. L217F PML did respond with increased SUMO2/3 conjugation that facilitated RNF4 engagement but failed to reach the threshold of SUMO1 conjugation required to recruit TOPORS. Thus, neither mutant accumulated the appropriate polyubiquitin signal required for p97 binding. These PML mutants have revealed a convergence of SUMO1, SUMO2/3, TOPORS, and RNF4 that facilitates the arsenic-induced degradation of PML.
Insights
Arsenic resistance in leukemia can arise from mutations in the promyelocytic leukemia (PML) protein. Understanding these mutations reveals how PML protein degradation is regulated, offering insights into treatment resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Arsenic trioxide is a crucial treatment for acute promyelocytic leukemia (APL).
- It functions by degrading the oncogenic PML-RARα fusion protein.
- Drug resistance can develop due to mutations in the PML protein.
Purpose of the Study:
- To investigate the molecular mechanisms underlying arsenic resistance in APL.
- To elucidate how specific PML mutations affect arsenic-induced protein degradation.
Main Methods:
- Reconstitution of PML-/- cells with wild-type and mutant PML-V proteins (A216T, L217F).
- Analysis of SUMOylation, ubiquitination, and recruitment of key regulatory proteins (RNF4, TOPORS).
- Assessment of polyubiquitin signal formation for p97 binding.
Main Results:
- Both A216T and L217F PML mutants exhibited resistance to arsenic-induced degradation.
- A216T PML failed to recruit RNF4 and TOPORS due to lack of SUMOylation.
- L217F PML showed impaired SUMO1 conjugation, hindering TOPORS recruitment and subsequent degradation.
Conclusions:
- PML mutations confer arsenic resistance through distinct biochemical alterations in protein degradation pathways.
- The study highlights the critical roles of SUMO1, SUMO2/3, RNF4, and TOPORS in arsenic-mediated PML clearance.
- These findings provide a mechanistic basis for arsenic resistance and potential therapeutic strategies.
Related Concept Videos
Abnormal Proliferation
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

